Stocks
Boundless Bio, Inc.BOLD
NASDAQHealthcareBiotechnology$2.34
Price as of · delayed, not real-time
A clinical-stage oncology company developing targeted therapies for cancers driven by extrachromosomal DNA (ecDNA), a genetic abnormality linked to tumor growth and drug resistance. Its lead candidate, BBI-355, is in Phase 1/2 trials for solid tumors, and the company went public in early 2024, drawing attention for its novel approach to treating aggressive cancers.
52W Range: $0.96-$3.16
Congressional Interest in Boundless Bio, Inc. (BOLD)
No congressional trades have been disclosed for Boundless Bio, Inc. (BOLD) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading BOLD?
No congressional trades found for this stock.